Adi Goldin - Collplant Biotechnologies Director
| CLGN Stock | USD 5.95 0.24 3.88% |
Director
Mr. Adi Goldin serves Director at Collplant Holdings Ltd since May 20, 2010. He is a member of the Finance and Identification committees. During June 24, 2016 and January 14, 2018, he has served as Temporary Chairman of the Board at the Company. His work experience includes the following roles Lawyer, Vice President at Docor International Management Ltd, Chief Executive Officer at Softlib Ltd and Director at a variety of companies. He holds a LLB degree, a Bachelors degree in Economics and a Masters degree in Economics, all from Tel Aviv University. since 2018.
| Age | 42 |
| Tenure | 6 years |
| Address | Weizmann Science Park, Rehovot, Israel, 7670104 |
| Phone | 972 73 232 5600 |
| Web | https://www.collplant.com |
Collplant Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1306) % which means that it has lost $0.1306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2316) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of May 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 4th of May 2024, Intangible Assets is likely to grow to about 265.7 K, while Total Assets are likely to drop about 18.2 M.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Mark Ternouth | Virax Biolabs Group | 56 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.13 |
Collplant Biotechnologies Leadership Team
Elected by the shareholders, the Collplant Biotechnologies' board of directors comprises two types of representatives: Collplant Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collplant. The board's role is to monitor Collplant Biotechnologies' management team and ensure that shareholders' interests are well served. Collplant Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collplant Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michal Roytman, VP Marketing | ||
| Abraham Havron, Independent Director | ||
| Pr Shoseyov, Founder Scientist | ||
| Oded Shoseyov, Chief Scientific Officer | ||
| Philippe Bensimon, Vice President-Regulation & Quality Control | ||
| Adi Goldin, Director | ||
| Elana Gazal, Vice Development | ||
| Shomrat Shurtz, Vice President - Commercialization | ||
| Revital MandilLevin, Chief Business Development Officer | ||
| Elan Penn, External Director | ||
| Jonathan Rigby, Chairman of the Board | ||
| Talya Zavchon, Finance Director | ||
| Eran Rotem, Vice President - Finance | ||
| David Tsur, Chairman of the Board | ||
| Oren Fahimipoor, Vice Operations | ||
| Dana Erlich, Internal Auditor | ||
| Gili Hart, External Director | ||
| Eran CPA, Deputy CFO | ||
| Ilana Belzer, Vice President - Operations | ||
| Yehiel Tal, CEO Director | ||
| Nadav Orr, Vice President - Research & Development | ||
| Hadas Horowitz, Vice Resources | ||
| Scott Burell, Independent Director |
Collplant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collplant Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (16.95) % | ||||
| Current Valuation | 47.32 M | ||||
| Shares Outstanding | 11.45 M | ||||
| Shares Owned By Insiders | 10.10 % | ||||
| Shares Owned By Institutions | 12.23 % | ||||
| Number Of Shares Shorted | 8.89 K | ||||
| Price To Earning | 92.60 X |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Collplant Stock
| 0.72 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.59 | VTYX | Ventyx Biosciences Financial Report 9th of May 2024 | PairCorr |
| 0.59 | GOSS | Gossamer Bio Earnings Call This Week | PairCorr |
| 0.55 | LYRA | Lyra TherapeuticsInc Financial Report 10th of May 2024 | PairCorr |
| 0.45 | GLUE | Monte Rosa Therapeutics Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.Note that the Collplant Biotechnologies information on this page should be used as a complementary analysis to other Collplant Biotechnologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Collplant Stock analysis
When running Collplant Biotechnologies' price analysis, check to measure Collplant Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collplant Biotechnologies is operating at the current time. Most of Collplant Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Collplant Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collplant Biotechnologies' price. Additionally, you may evaluate how the addition of Collplant Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Collplant Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.962 | Quarterly Revenue Growth 4.155 | Return On Assets (0.13) | Return On Equity (0.23) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.